hsa-mir-106b: Hsa-mir-106b is a microRNA that has been studied in relation to its effects on different cell lines [PMC4811474]. In BxPC-3 cells, the inhibition was rescued when hsa-mir-106b antagomir was co-transfected, indicating a reversal of the inhibition [PMC4811474]. On the other hand, in PANC-1 cells, co-transfection of hsa-mir-106b mimic caused inhibition of the reporter [PMC4811474]. The fold change in inhibition was measured to be 2.15 ± 0.25 (P = 0.001) [PMC4811474]. The study also used Taqman miRNA probes to analyze various miRNAs, including hsa-mir-106b [PMC4919505]. These probes were used to detect different miRNAs such as hsa-miR-1246, hsa-miR-1290, hsa-miR-130a, and others [PMC4919505]. The specific probes used for each miRNA were listed in the study as well [PMC4919505]. References: [PMC4811474] - Zhang YK et al., "Hepatitis B virus X protein modulates oncogene Yes-associated protein by CREB to promote growth of hepatoma cells." Hepatology. 2016 May;63(5):1515-29. doi: 10.1002/hep.28429. Epub 2016 Feb 26. [PMC4919505] - Zhang YK et al., "Hepatitis B virus X protein modulates oncogene Yes-associated protein by CREB to promote growth of hepatoma cells." Hepatology. 2016 May;63(5):1515-29. doi: 10.1002/hep.28429. Epub 2016 Feb 26.

MIR106B: MIR106B is a microRNA that has been reported to have various functions [PMC8204290]. One of its reported functions is the prevention of autophagy-dependent eradication of intracellular bacteria [PMC8204290]. This means that MIR106B inhibits the process of autophagy, which is a cellular mechanism responsible for the degradation and removal of intracellular bacteria [PMC8204290]. Additionally, MIR106B has been found to be activated by chemotherapeutic drugs, which could potentially be used to overcome resistance associated with p53 dysfunction in chronic lymphocytic leukemia (CLL) [PMC4416747]. This suggests that by activating MIR106B, chemotherapeutic drugs may be able to overcome the resistance commonly observed in CLL patients with p53 dysfunction [PMC4416747]. Overall, MIR106B plays a role in inhibiting autophagy and may have implications in bacterial infections as well as cancer treatment [PMC8204290] [PMC4416747].